Limits...
JBP485 promotes tear and mucin secretion in ocular surface epithelia.

Nakamura T, Hata Y, Nagata M, Yokoi N, Yamaguchi S, Kaku T, Kinoshita S - Sci Rep (2015)

Bottom Line: Tear film contains ocular mucins and is essential for maintaining the homeostasis of the wet ocular surface.Since there are a limited number of clinical options for the treatment of DES, additional novel treatments are needed to improve the clinical results.Moreover, JBP485 clinically improved corneal epithelial damage in a mouse dry eye model.

View Article: PubMed Central - PubMed

Affiliation: 1] Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan [2] Research Center for Inflammation and Regenerative Medicine, Doshisha University, Kyoto, Japan.

ABSTRACT
Dry eye syndrome (DES), a multifactorial disease of the tears and ocular surface, is one of the most common ocular disorders. Tear film contains ocular mucins and is essential for maintaining the homeostasis of the wet ocular surface. Since there are a limited number of clinical options for the treatment of DES, additional novel treatments are needed to improve the clinical results. In this study, we found that placental extract-derived dipeptide (JBP485) clearly promoted the expression and secretion of gel-forming mucin 5ac (Muc5ac) in rabbit conjunctival epithelium. JBP485 also elevated the expression level of cell surface-associated mucins (Muc1/4/16) in rabbit corneal epithelium. The Schirmer tear test results indicated that JBP485 induced tear secretion in the rabbit model. Moreover, JBP485 clinically improved corneal epithelial damage in a mouse dry eye model. Thus, our data indicate that JBP485 efficiently promoted mucin and aqueous tear secretion in rabbit ocular surface epithelium and has the potential to be used as a novel treatment for DES.

No MeSH data available.


Related in: MedlinePlus

JBP485 repairs corneal epithelial damage in a mouse dry eye model.Fluorescent slit-lamp photographs of mouse eyes with or without JBP485 treatment for up to 15 days (A). Corneal fluorescein grading score at each time point after the topical application of JBP485 (B). * p < 0.05 (n = 10).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4440520&req=5

f8: JBP485 repairs corneal epithelial damage in a mouse dry eye model.Fluorescent slit-lamp photographs of mouse eyes with or without JBP485 treatment for up to 15 days (A). Corneal fluorescein grading score at each time point after the topical application of JBP485 (B). * p < 0.05 (n = 10).

Mentions: Following our findings demonstrating that JBP485 accelerates not only mucin secretion but also aqueous tear production, we investigated whether or not a topical application of JBP485 might be useful for the treatment of dry eye disease. Due to the fact that a rabbit dry eye model is difficult to establish and is too invasive and unstable to be used for evaluation, we used a simple mouse model of experimentally induced dry eye disease. Before the experiment, we confirmed that all mice showed reduced tear volume and resultant superficial punctate keratitis (SPK) on the cornea (Fig. 8A). Six days after the topical application of JBP485 (100 μM), SPK on the mice corneas were reduced in comparison to the controls (Fig. 8A). Fifteen days after the topical application of JBP485, SPK on the mice corneas was further reduced and corneal damage had clearly improved (Fig. 8A). In fact, we found that his effect was statistically significant (Fig. 8B). These findings suggest that JBP485 is useful in treating experimental dry eye conditions.


JBP485 promotes tear and mucin secretion in ocular surface epithelia.

Nakamura T, Hata Y, Nagata M, Yokoi N, Yamaguchi S, Kaku T, Kinoshita S - Sci Rep (2015)

JBP485 repairs corneal epithelial damage in a mouse dry eye model.Fluorescent slit-lamp photographs of mouse eyes with or without JBP485 treatment for up to 15 days (A). Corneal fluorescein grading score at each time point after the topical application of JBP485 (B). * p < 0.05 (n = 10).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4440520&req=5

f8: JBP485 repairs corneal epithelial damage in a mouse dry eye model.Fluorescent slit-lamp photographs of mouse eyes with or without JBP485 treatment for up to 15 days (A). Corneal fluorescein grading score at each time point after the topical application of JBP485 (B). * p < 0.05 (n = 10).
Mentions: Following our findings demonstrating that JBP485 accelerates not only mucin secretion but also aqueous tear production, we investigated whether or not a topical application of JBP485 might be useful for the treatment of dry eye disease. Due to the fact that a rabbit dry eye model is difficult to establish and is too invasive and unstable to be used for evaluation, we used a simple mouse model of experimentally induced dry eye disease. Before the experiment, we confirmed that all mice showed reduced tear volume and resultant superficial punctate keratitis (SPK) on the cornea (Fig. 8A). Six days after the topical application of JBP485 (100 μM), SPK on the mice corneas were reduced in comparison to the controls (Fig. 8A). Fifteen days after the topical application of JBP485, SPK on the mice corneas was further reduced and corneal damage had clearly improved (Fig. 8A). In fact, we found that his effect was statistically significant (Fig. 8B). These findings suggest that JBP485 is useful in treating experimental dry eye conditions.

Bottom Line: Tear film contains ocular mucins and is essential for maintaining the homeostasis of the wet ocular surface.Since there are a limited number of clinical options for the treatment of DES, additional novel treatments are needed to improve the clinical results.Moreover, JBP485 clinically improved corneal epithelial damage in a mouse dry eye model.

View Article: PubMed Central - PubMed

Affiliation: 1] Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan [2] Research Center for Inflammation and Regenerative Medicine, Doshisha University, Kyoto, Japan.

ABSTRACT
Dry eye syndrome (DES), a multifactorial disease of the tears and ocular surface, is one of the most common ocular disorders. Tear film contains ocular mucins and is essential for maintaining the homeostasis of the wet ocular surface. Since there are a limited number of clinical options for the treatment of DES, additional novel treatments are needed to improve the clinical results. In this study, we found that placental extract-derived dipeptide (JBP485) clearly promoted the expression and secretion of gel-forming mucin 5ac (Muc5ac) in rabbit conjunctival epithelium. JBP485 also elevated the expression level of cell surface-associated mucins (Muc1/4/16) in rabbit corneal epithelium. The Schirmer tear test results indicated that JBP485 induced tear secretion in the rabbit model. Moreover, JBP485 clinically improved corneal epithelial damage in a mouse dry eye model. Thus, our data indicate that JBP485 efficiently promoted mucin and aqueous tear secretion in rabbit ocular surface epithelium and has the potential to be used as a novel treatment for DES.

No MeSH data available.


Related in: MedlinePlus